Your activity: 2 p.v.

Lanreotide: Drug information

Lanreotide: Drug information
(For additional information see "Lanreotide: Patient drug information")

For abbreviations, symbols, and age group definitions used in Lexicomp (show table)
Brand Names: US
  • Somatuline Depot
Brand Names: Canada
  • Somatuline Autogel
Pharmacologic Category
  • Somatostatin Analog
Dosing: Adult
Acromegaly

Acromegaly:

Note : For use in patients with persistent disease following surgery or in whom surgery is not appropriate. If clinical and/or biochemical response is inadequate at maximum dosage of lanreotide, consider alternative agents or starting combination therapy (ACG [Melmed 2018]; ES [Katznelson 2014]).

SUBQ: Initial: 90 mg every 4 weeks for 3 months; after initial 3 months, adjust dose as necessary based on clinical response, growth hormone (GH) levels, and/or insulin-like growth factor 1 (IGF-1) levels as follows:

GH ≤1 ng/mL, IGF-1 normal, symptoms controlled: SUBQ: Decrease dose to 60 mg every 4 weeks; once stabilized on 60 mg every 4 weeks, may consider regimen of 120 mg every 6 or 8 weeks (extended-interval dosing).

GH >1 to 2.5 ng/mL, IGF-1 normal, symptoms controlled: SUBQ: Continue 90 mg every 4 weeks; once stabilized on 90 mg every 4 weeks, may consider regimen of 120 mg every 6 or 8 weeks (extended-interval dosing).

GH >2.5 ng/mL, IGF-1 elevated and/or symptoms uncontrolled : SUBQ: Increase to 120 mg every 4 weeks. If GH remains >1 ng/mL and/or IGF-1 remains elevated after >6 months, individualized doses of 180 mg every 4 weeks or 120 mg every 3 weeks may be considered (Giustina 2017).

Carcinoid syndrome

Carcinoid syndrome:

Note: For patients experiencing breakthrough symptoms, supplementary doses of SUBQ octreotide may be necessary (Fisher 2018).

SUBQ: 120 mg every 4 weeks; in patients already receiving lanreotide for treatment of gastroenteropancreatic neuroendocrine tumors, do not administer an additional dose for carcinoid syndrome.

Gastroenteropancreatic neuroendocrine tumors

Gastroenteropancreatic neuroendocrine tumors: SUBQ: 120 mg every 4 weeks until disease progression or unacceptable toxicity.

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Adult

Acromegaly:

CrCl ≥60 mL/minute: No dosage adjustment necessary.

CrCl <60 mL/minute: Initial dose: 60 mg every 4 weeks for 3 months; adjust dose as necessary based on clinical response, growth hormone levels, and/or insulin-like growth factor 1 levels (refer to adult dosing). Use extended-interval dosing regimens (120 mg every 6 or 8 weeks) with caution.

Carcinoid syndrome or gastroenteropancreatic neuroendocrine tumors:

CrCl ≥30 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling, however, total clearance of lanreotide 120 mg is not affected.

CrCl <30 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).

Dosing: Hepatic Impairment: Adult

Acromegaly:

Mild impairment (Child-Pugh class A): No dosage adjustment necessary.

Moderate to severe impairment (Child-Pugh classes B and C): Initial dose: 60 mg every 4 weeks for 3 months; adjust dose as necessary based on clinical response, growth hormone levels, and/or insulin-like growth factor 1 levels (refer to adult dosing). Use extended-interval dosing regimens (120 mg every 6 or 8 weeks) with caution.

Carcinoid syndrome or gastroenteropancreatic neuroendocrine tumors: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).

Dosing: Older Adult

Refer to adult dosing.

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Solution, Subcutaneous:

Generic: 120 mg/0.5 mL (0.5 mL)

Solution, Subcutaneous [preservative free]:

Somatuline Depot: 120 mg/0.5 mL (0.5 mL); 60 mg/0.2 mL (0.2 mL); 90 mg/0.3 mL (0.3 mL)

Generic Equivalent Available: US

Yes

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Solution, Subcutaneous:

Somatuline Autogel: 60 mg/0.5 mL (0.5 mL); 90 mg/0.5 mL (0.5 mL); 120 mg/0.5 mL (0.5 mL)

Administration: Adult

SUBQ: Administer by deep SUBQ injection (only) into superior outer quadrant of buttock. Alternate injection sites between the right and left sides from one injection to the next. Remove sealed pouch from refrigerator 30 minutes prior to administration in order to reach room temperature. Keep pouch sealed until just prior to injection.

Use: Labeled Indications

Acromegaly: Long-term treatment of acromegaly in patients who have had an inadequate response to surgery and/or radiotherapy, or for whom surgery and/or radiotherapy is not an option.

Carcinoid syndrome: Treatment of carcinoid syndrome in adults (to reduce the frequency of short acting somatostatin analog rescue therapy).

Gastroenteropancreatic neuroendocrine tumors: Treatment (to improve progression-free survival) of unresectable, well- or moderately-differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adults.

Medication Safety Issues
Sound-alike/look-alike issues:

Lanreotide may be confused with octreotide, pasireotide

Somatuline may be confused with Soma, somatropin, SUMAtriptan

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.

>10%:

Cardiovascular: Bradycardia (3% to 18%), hypertension (5% to 14%)

Central nervous system: Headache (5% to 16%)

Dermatologic: Injection site pruritus (≤17%), rash at injection site (≤15%)

Endocrine & metabolic: Diabetes mellitus (≤14%), hyperglycemia (≤14%), hypoglycemia (≤14%), weight loss (5% to 11%)

Gastrointestinal: Diarrhea (26% to 65%), abdominal pain (7% to 34%), cholelithiasis (2% to 27%), vomiting (5% to 19%), flatulence (6% to 15%), nausea (9% to 11%)

Hematologic & oncologic: Anemia (3% to 14%)

Hepatic: Gallbladder sludge (≤20%)

Immunologic: Antibody development (≤11%)

Local: Inflammation at injection site (≤22%), injection site reaction (≤22%), pain at injection site (≤22%), residual mass at injection site (≤22%), induration at injection site (≤17%), injection site nodule (≤17%), bleeding at injection site (≤15%), discomfort at injection site (≤15%), hematoma at injection site (≤15%), injection site extravasation (≤15%), injection site granuloma (≤15%), swelling at injection site (≤15%)

Neuromuscular & skeletal: Musculoskeletal pain (19%)

1% to 10%:

Cardiovascular: Sinus bradycardia (3% to 7%)

Central nervous system: Dizziness (7% to 9%), depression (7%)

Gastrointestinal: Loose stools (6% to 9%), constipation (5% to 8%)

Neuromuscular & skeletal: Arthralgia (7% to 10%), muscle spasm (5%)

Respiratory: Dyspnea (6%)

<1%, postmarketing, and/or case reports: Abscess at injection site, anaphylaxis, angioedema, aortic insufficiency, cholecystitis, hypothyroidism, mitral valve insufficiency, pancreatitis, steatorrhea

Contraindications

Hypersensitivity to lanreotide or any component of the formulation

Canadian labeling: Additional contraindications (not in the US labeling): Hypersensitivity to somatostatin or related peptides; complicated, untreated bile duct lithiasis

Warnings/Precautions

Concerns related to adverse effects:

• Cholelithiasis: May reduce gall bladder motility, leading to gall stone formation (may be dose- or duration-related). Cholelithiasis and complications of cholelithiasis (eg, cholecystitis, cholangitis, pancreatitis) requiring cholecystectomy have been reported.

• Gastrointestinal effects: Diarrhea and loose stools may occur (may affect intestinal absorption of concurrently administered medication); abdominal pain may also occur.

• Hyper-/hypoglycemia: Inhibition of insulin and glucagon secretion may affect glucose regulation, leading to hyper- or hypoglycemia. Use with caution in patients with diabetes; may require dosage adjustments in antidiabetic therapy.

• Hypersensitivity: Allergic reactions, including angioedema and anaphylaxis, have been reported.

• Thyroid disorders: Slight decreases in thyroid function have been observed during treatment for acromegaly. The incidence of clinical hypothyroidism is rare.

Disease-related concerns:

• Cardiac disorders: Bradycardia, sinus bradycardia, and hypertension have been observed with therapy. Use with caution in patients with preexisting cardiac disease. Patients without preexisting cardiac disease may experience a decrease in heart rate though not to the level of bradycardia. Appropriate medical therapy should be initiated if patients develop symptomatic bradycardia.

• Hepatic impairment: Use with caution in patients with acromegaly with moderate to severe hepatic impairment (systemic exposure may be increased); lanreotide has not been studied in patients with neuroendocrine tumors with hepatic impairment.

• Renal impairment: Use with caution in patients with acromegaly with moderate to severe renal impairment.

Metabolism/Transport Effects

None known.

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.

Androgens: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects. Risk C: Monitor therapy

Antidiabetic Agents: May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents. Risk C: Monitor therapy

Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. Risk C: Monitor therapy

Bradycardia-Causing Agents: May enhance the bradycardic effect of other Bradycardia-Causing Agents. Risk C: Monitor therapy

Bromocriptine: Somatostatin Analogs may increase the serum concentration of Bromocriptine. Somatostatin Analogs may also delay bromocriptine absorption and time to maximum plasma concentrations. Risk C: Monitor therapy

Ceritinib: Bradycardia-Causing Agents may enhance the bradycardic effect of Ceritinib. Management: If this combination cannot be avoided, monitor patients for evidence of symptomatic bradycardia, and closely monitor blood pressure and heart rate during therapy. Risk D: Consider therapy modification

Codeine: Somatostatin Analogs may decrease serum concentrations of the active metabolite(s) of Codeine. Specifically, the concentrations of the active metabolite morphine may be reduced. Risk C: Monitor therapy

Copper Cu 64 Dotatate: Somatostatin Analogs may diminish the diagnostic effect of Copper Cu 64 Dotatate. Management: Imaging with copper Cu 64 dotatate positron emission tomography (PET) should be performed just prior to dosing with somatostatin analogs. If on somatostatin analogs, stop long-acting agents 28 days before, and short-acting agents 2 days before, imaging. Risk D: Consider therapy modification

CycloSPORINE (Systemic): Somatostatin Analogs may decrease the serum concentration of CycloSPORINE (Systemic). Risk C: Monitor therapy

Fexinidazole: Bradycardia-Causing Agents may enhance the arrhythmogenic effect of Fexinidazole. Risk X: Avoid combination

Fingolimod: Bradycardia-Causing Agents may enhance the bradycardic effect of Fingolimod. Management: Consult with the prescriber of any bradycardia-causing agent to see if the agent could be switched to an agent that does not cause bradycardia prior to initiating fingolimod. If combined, perform continuous ECG monitoring after the first fingolimod dose. Risk D: Consider therapy modification

Gallium Ga 68 Dotatate: Somatostatin Analogs may diminish the diagnostic effect of Gallium Ga 68 Dotatate. Specifically, a false negative PET scan may occur if Gallium GA 68 Dotatate is used during treatment with somatostatin analogs. Management: It is recommended to image with gallium Ga 68 dotatate positron emission tomography (PET) just prior to dosing with long-acting somatostatin analogs. Short-acting somatostatin analogs can be used up to 24 hours before imaging with gallium Ga 68 dotatate. Risk D: Consider therapy modification

Gallium Ga 68 Dotatoc: Somatostatin Analogs may diminish the diagnostic effect of Gallium Ga 68 Dotatoc. Management: Imaging with gallium Ga 68 dotatoc positron emission tomography (PET) should be performed just prior to dosing with long-acting somatostatin analogs. Short-acting somatostatin analogs can be used up to 24 hours before imaging with gallium Ga 68 dotatoc. Risk D: Consider therapy modification

Herbal Products with Glucose Lowering Effects: May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents. Risk C: Monitor therapy

Hypoglycemia-Associated Agents: May enhance the hypoglycemic effect of other Hypoglycemia-Associated Agents. Risk C: Monitor therapy

Ivabradine: Bradycardia-Causing Agents may enhance the bradycardic effect of Ivabradine. Risk C: Monitor therapy

Lacosamide: Bradycardia-Causing Agents may enhance the AV-blocking effect of Lacosamide. Risk C: Monitor therapy

Lutetium Lu 177 Dotatate: Somatostatin Analogs may diminish the therapeutic effect of Lutetium Lu 177 Dotatate. Specifically, the therapeutic effect of Lutetium Lu 177 Dotatate may be diminished if the timing of Somatostatin Analog administration is not carried out as recommended. Management: Discontinue long-acting somatostatin analogs at least 4 weeks and short-acting octreotide at least 24 hours prior to lutetium Lu 177 dotatate dose. Administer short and long-acting octreotide during treatment as recommended. See full interaction monograph Risk D: Consider therapy modification

Macimorelin: Somatostatin Analogs may diminish the diagnostic effect of Macimorelin. Risk X: Avoid combination

Maitake: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects. Risk C: Monitor therapy

Midodrine: May enhance the bradycardic effect of Bradycardia-Causing Agents. Risk C: Monitor therapy

Monoamine Oxidase Inhibitors: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects. Risk C: Monitor therapy

Opioid Agonists: May diminish the analgesic effect of Somatostatin Analogs. Opioid Agonists may enhance the analgesic effect of Somatostatin Analogs. Risk C: Monitor therapy

Ozanimod: May enhance the bradycardic effect of Bradycardia-Causing Agents. Risk C: Monitor therapy

Pegvisomant: Somatostatin Analogs may enhance the adverse/toxic effect of Pegvisomant. Specifically, this combination may increase the risk for significant elevations of liver enzymes. Risk C: Monitor therapy

Pegvisomant: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects. Risk C: Monitor therapy

Ponesimod: Bradycardia-Causing Agents may enhance the bradycardic effect of Ponesimod. Management: Avoid coadministration of ponesimod with drugs that may cause bradycardia when possible. If combined, monitor heart rate closely and consider obtaining a cardiology consult. Do not initiate ponesimod in patients on beta-blockers if HR is less than 55 bpm. Risk D: Consider therapy modification

Prothionamide: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects. Risk C: Monitor therapy

Quinolones: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects. Quinolones may diminish the therapeutic effect of Agents with Blood Glucose Lowering Effects. Specifically, if an agent is being used to treat diabetes, loss of blood sugar control may occur with quinolone use. Risk C: Monitor therapy

Salicylates: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects. Risk C: Monitor therapy

Selective Serotonin Reuptake Inhibitors: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects. Risk C: Monitor therapy

Sincalide: Drugs that Affect Gallbladder Function may diminish the therapeutic effect of Sincalide. Management: Consider discontinuing drugs that may affect gallbladder motility prior to the use of sincalide to stimulate gallbladder contraction. Risk D: Consider therapy modification

Siponimod: Bradycardia-Causing Agents may enhance the bradycardic effect of Siponimod. Management: Avoid coadministration of siponimod with drugs that may cause bradycardia. If combined, consider obtaining a cardiology consult regarding patient monitoring. Risk D: Consider therapy modification

Tofacitinib: May enhance the bradycardic effect of Bradycardia-Causing Agents. Risk C: Monitor therapy

Reproductive Considerations

Because normalization of insulin-like growth factor 1 and growth hormone may restore fertility in premenopausal patients with acromegaly, patients who could become pregnant should use adequate contraception during treatment.

Lanreotide may be used for patients with acromegaly who are trying to conceive; discontinue once pregnancy is confirmed (ESE [Luger 2021]). The Endocrine Society suggests discontinuing long-acting formulations of somatostatin analogs approximately 2 months before attempts to conceive; short-acting octreotide may be used until conception if needed (ES [Katznelson 2014]).

Pregnancy Considerations

Information related to the use of lanreotide for the treatment of acromegaly in pregnancy is limited (de Menis 1999; Teltayev 2017). If treatment for acromegaly is required during pregnancy for worsening symptoms (eg, headaches or evidence of tumor growth), alternative agents are recommended. Monitoring of insulin-like growth factor 1 (IGF-1) and/or growth hormone (GH) is not recommended during pregnancy, as an active placental GH variant present in maternal blood limits the usefulness of the results (ES [Katznelson 2014]; ESE [Luger 2021]).

Information related to the use of lanreotide in pregnant patients with gastroenteropancreatic neuroendocrine tumors is limited (Meoni 2020).

Breastfeeding Considerations

It is not known if lanreotide is present in breast milk.

Due to the potential for serious adverse reactions in the breastfed infant (including possible effects on glucose metabolism and bradycardia), breastfeeding is not recommended by the manufacturer during treatment and for 6 months after the last lanreotide dose.

Monitoring Parameters

Serum growth hormone (GH) and insulin-like growth factor 1 (IGF-1) at 3 months and as clinically indicated in acromegaly patients (obtain levels 6 weeks after dose adjustment when switching to extended-interval dosing); blood glucose, glycemic control and antidiabetic regimen (patients with diabetes mellitus) should be assessed following initiation, then periodically or following dosage adjustments; thyroid function (if clinically indicated); heart rate; gallbladder monitoring. Monitor for cholelithiasis if clinically indicated; routine gallbladder ultrasound is not necessary (ES [Katznelson 2014]).

Reference Range

Age-normalized serum insulin-like growth factor 1 (IGF-1) and a random growth hormone (GH) <1 mcg/L correlate with control of acromegaly; consider targeting postoperative GH level <0.4 mcg/L if ultra-sensitive GH assay is available; use of the same IGF-1 and GH assay in the same patient throughout management is suggested (ACG [Melmed 2018], ES [Katznelson 2014]).

Mechanism of Action

Lanreotide is a synthetic octapeptide analogue of natural somatostatin which is a peptide inhibitor of multiple endocrine, neuroendocrine, and exocrine mechanisms. Lanreotide displays a greater affinity for somatostatin type 2 (SSTR2) and type 5 (SSTR5) receptors found in pituitary gland, pancreas, and growth hormone (GH) secreting neoplasms of pituitary gland and a lesser affinity for somatostatin receptors 1, 3, and 4. Lanreotide reduces GH secretion and also reduces the levels of insulin-like growth factor 1.

Pharmacokinetics

Distribution: 15.14 L (Trocóniz 2009)

Bioavailability: 69% to ~78%

Half-life elimination: 23 to 30 days

Time to peak, plasma: 7 to 12 hours (Trocóniz 2009)

Excretion: Urine (<5% as unchanged drug); feces (<0.5% as unchanged drug)

Pharmacokinetics: Additional Considerations

Altered kidney function: In patients with ESRD, there is approximately a 2-fold decrease in total serum clearance, with a consequent 2-fold increase in half-life and AUC.

Hepatic function impairment: A 30% reduction in clearance was observed in patients with moderate to severe hepatic impairment.

Older adult: Compared with healthy younger subjects, elderly subjects showed an 85% increase in half-life and a 65% increase in mean residence time.

Pricing: US

Solution (Lanreotide Acetate Subcutaneous)

120 mg/0.5 mL (per 0.5 mL): $10,671.19

Solution (Somatuline Depot Subcutaneous)

60 mg/0.2 mL (per 0.2 mL): $7,305.60

90 mg/0.3 mL (per 0.3 mL): $9,729.60

120 mg/0.5 mL (per 0.5 mL): $11,474.40

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Brand Names: International
  • Ipstyl (DK, IT, NO);
  • Somatuiline (LB);
  • Somatulin (UA);
  • Somatulina (AT, ES);
  • Somatuline (AT, BE, CN, CZ, EE, GR, HR, JO, JP, LT, LU, LV, NL, PL, PT, RO, RU, SI, SK, TR);
  • Somatuline Autogel (AR, AU, BG, CH, CL, CO, CR, CY, DE, DO, EG, GB, GT, HN, IE, IL, KR, MY, NI, PA, SE, SV, TH, TW);
  • Somatuline Depot (BB);
  • Somatuline LA (AU);
  • Somatuline LP (FR);
  • Somatuline P.R. (CZ, FI, HK, IL, SG)


For country code abbreviations (show table)
  1. Caplin ME, Pavel M, Ćwikła JB, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014;371(3):224-233. doi: 10.1056/NEJMoa1316158. [PubMed 25014687]
  2. Caron P, Beckers A, Cullen DR, et al, “Efficacy of the New Long-Acting Formulation of Lanreotide (Lanreotide Autogel) in the Management of Acromegaly,” J Clin Endocrinol Metab, 2002, 87(1):99-104. [PubMed 17489310]
  3. de Menis E, Billeci D, Marton E, et al, "Uneventful Pregnancy in an Acromegalic Patient Treated With Slow-Release Lanreotide: A Case Report," J Clin Endocrinol Metab, 1999, 84(4):1489. [PubMed 10199803]
  4. Fisher GA Jr, Wolin EM, Liyanage N, et al; ELECT Study Group. Patient-reported symptom control of diarrhea and flushing in patients with neuroendocrine tumors treated with lanreotide depot/autogel: results from a randomized, placebo-controlled, double-blind and 32-week open-label study. Oncologist. 2018;23(1):16-24. doi:10.1634/theoncologist.2017-0284 [PubMed 29038234]
  5. Giustina A, Mazziotti G, Cannavò S, et al. High-dose and high-frequency lanreotide autogel in acromegaly: a randomized, multicenter study. J Clin Endocrinol Metab. 2017;102(7):2454-2464. doi: 10.1210/jc.2017-00142. [PubMed 28419317]
  6. Katznelson L, Atkinson JL, Cook DM, Ezzat SZ, Hamrahian AH, Miller KK; American Association of Clinical Endocrinologists. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly--2011 update. Endocr Pract. 2011;17(suppl 4):1-44. [PubMed 21846616]
  7. Katznelson L, Laws ER Jr, Melmed S, et al; Endocrine Society. Acromegaly: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(11):3933-3951. doi: 10.1210/jc.2014-2700. [PubMed 25356808]
  8. Luger A, Broersen LHA, Biermasz NR, et al. ESE clinical practice guideline on functioning and nonfunctioning pituitary adenomas in pregnancy. Eur J Endocrinol. 2021;185(3):G1-G33. doi:10.1530/EJE-21-0462 [PubMed 34425558]
  9. Melmed S, Bronstein MD, Chanson P, et al. A consensus statement on acromegaly therapeutic outcomes. Nat Rev Endocrinol. 2018;14(9):552-561. [PubMed 30050156]
  10. Meoni G, Giommoni E, Petreni P, et al. Somatostatin analogs in pregnant patients with neuroendocrine tumor. Anticancer Drugs. 2020;31(10):1096-1098. doi:10.1097/CAD.0000000000000967 [PubMed 32590392]
  11. Rasmussen E, Eriksson B, Oberg K, et al, “Selective Effects of Somatostatin Analogs on Human Drug-Metabolizing Enzymes,” Clin Pharmacol Ther, 1998, 64(2):150-9. [PubMed 9728895]
  12. Reubi JC, Waser B, Schaer JC, et al, “Somatostatin Receptor sst1-sst5 Expression in Normal and Neoplastic Human Tissues Using Receptor Autoradiography With Subtype-Selective Ligands,” Eur J Nucl Med, 2001, 28(7):836-46. [PubMed 11504080]
  13. Somatuline Autogel (lanreotide) [product monograph]. Mississauga, Ontario, Canada: Ipsen Biopharmaceuticals Canada Inc; March 2021.
  14. Somatuline Depot (lanreotide) [prescribing information]. Basking Ridge, NJ: Ipsen Biopharmaceuticals, Inc; June 2019.
  15. Teltayev D, Akshulakov S, Ryskeldiev N, et al. Pregnancy in women after successful acromegaly treatment, including surgical removal of pituitary adenoma and postoperative therapy using lanreotide acetate. Gynecol Endocrinol. 2017;33(sup1):50-51. doi: 10.1080/09513590.2017.1404240. [PubMed 29264984]
  16. Trocóniz IF, Cendrós JM, Peraire C, et al. Population pharmacokinetic analysis of lanreotide Autogel in healthy subjects: evidence for injection interval of up to 2 months. Clin Pharmacokinet. 2009;48(1):51-62. doi: 10.2165/0003088-200948010-00004. [PubMed 19071884]
Topic 10184 Version 222.0